ERYtech Pharma Enrolled Its Last Patient for Its Phase II GRASPALL Clinical Trial and Selects Philadelphia Science Center As US Headquarters

ERYtech Pharma announces the inclusion of its last patient in its Phase II clinical trial for relapsed Acute Lymphoblastic Leukaemia (ALL).

The main goal of this trial is to evaluate the pharmacokinetic, the pharmacodynamic and the safety of GRASPA(R), ERYtech Pharma’s new medicinal product. Twenty four patients, comprised of nine adults and nine children received at least one dose of GRASPA(R) , three other children and three adult patients received the control product, the free form of native E. coli L-Asparaginase.

David Liens, Chief Medical Officer at ERYtech Pharma stated that < >

ERYtech Pharma also announced that it has elected the Philadelphia University Science Center as their US operations base.

Pierre-Olivier Goineau, Co-founder of ERYtech Pharma, Chief Operations Officer and Business Development Director, comments on selecting the Science Center, “Philadelphia’s market potential is exceptional! ERYtech Pharma was looking for the best place to establish its first overseas operation and the Philadelphia life science market is the perfect match. We want to develop our business with the phenomenal concentration of bio-pharmaceutical companies nationwide”. “The dynamics of the life science community, and the large quantity of hospitals in the region played a key role in ERYtech Pharma’s final decision” said Yann Godfrin, Chief Executive Officer, Co-founder of ERYtech Pharma.

ERYtech’s business development strategy is to develop its own portfolio and to expand it through partnership agreement with major biotech and pharmaceutical companies. Based on its strong expertise and progress of its technological platform, ERYtech is open to discuss co-development projects with companies interested in testing different approaches with their compounds. Of particular interest are therapeutic enzymes in oncology or enzyme deficiency inherited disorders field, new product candidates in liver or bone marrow disease treatment.

About GRASPA(R) (click here for video)

About ERYtech Pharma (www.erytech.com)

ERYtech Pharma is a leading biotechnology company developing next generation medicinal products making a huge positive impact on the lives of patients with serious unmet clinical needs.

A pioneer in the encapsulation of therapeutic molecules inside red blood cells, it is developing a pipeline of innovative therapeutics in orphan indications or underserved subpopulation of high risk patient’s through its proprietary technology of entrapment and in-depth exploration of red cell physiologic properties.

ERYtech is focused in the fields of Haematology, Oncology and Metabolic Diseases. ERYtech Pharma’s most advanced product, GRASPA(R), has completed a Phase II clinical trial in leukaemia and is currently being evaluated in the indication of several solid tumours. Beyond GRASPA(R), ERYtech has several investigational compounds addressing specific unmet clinical needs through enhanced efficacy, better compliance, reduced dosage or increased safety profile.

About the Science Center (www.ScienceCenter.org)